Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: Best New Technology Solution for Ophthalmology
Lumenis Be., a leading energy-based medical device company for aesthetic and eye care applications, today announced that OptiLight has received the highly competitive MedTech Breakthrough Award for “Best New Technology Solution for Ophthalmology.” This year, MedTech’s range of health and medical technology categories attracted more than 3,900 nominations from over 15 countries, from which MedTech selected OptiLight for this prestigious recognition. The win follows Lumenis’ MedTech awards for Best Overall Medical Device Company in 2021 and Best New Surgical Technology Solution in 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005607/en/
(Graphic: Business Wire)
OptiLight is a groundbreaking, light-based treatment. It is the first and only light treatment FDA approved for management of dry eye disease, a very common condition that causes dry, gritty eyes and fluctuating vision for an estimated 49 million Americans.1 Lumenis’ patented, innovative Optimal Pulse Technology (OPT™) offers targeted, uniform, precise, and controlled treatment that safely and effectively breaks the vicious cycle of inflammation associated with dry eye disease.
“Dry eye disease is highly prevalent and difficult to manage, and traditional treatments like warm compresses and artificial tears treat the symptoms but not the underlying pathology,” said James Johnson, managing director, MedTech Breakthrough. “OptiLight is leading a revolution in managing dry eye disease with ‘breakthrough’ technology that allows doctors to treat patients quickly, in-office. With broad potential for tens of millions with dry eye disease, OptiLight stands out from the crowd to become our 2022 Best New Technology Solution for Ophthalmology.”
Lumenis introduced OptiLight in May 2021 and recently launched a national media campaign featuring singer-songwriter and actress Mandy Moore (This Is Us) to increase awareness for dry eye disease and encourage people who might be suffering from this condition to seek out a physician who offers OptiLight (www.TreatMyDryEye.com).
“We’re grateful to MedTech for honoring OptiLight for its innovation and impact in eye care,” said Lumenis CEO Tzipi Ozer-Armon. “Lumenis is committed to raising the bar for patients’ health by providing cutting-edge solutions and treatment innovations. As the only light-based treatment for dry eye disease, OptiLight has the power to elevate dry eye management and improve health and quality of life for millions of people around the world.”
|
1. Dana R et al. Patient-Reported Burden of Dry Eye Disease in the United States: Results of an Online Cross-Sectional Survey. Am J Ophthalmol. 2020 Aug; 216:7-17. |
About Lumenis
Lumenis is a leading energy-based medical device company for aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. It is regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis’ groundbreaking products have redefined medical treatments and have set numerous technological and clinical gold standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.
PB-00044810 Rev A
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005607/en/
Contact information
Colleen Ketchum
colleen.ketchum@precisionvh.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phenom Named Strategic Leader in 2025 Fosway 9-Grid™ for Talent & People Success for Second Consecutive Year29.10.2025 15:30:00 EET | Press release
Phenom, an applied AI company that helps organizations hire faster, develop better and retain longer, has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029195746/en/ Phenom has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. Fosway Group identifies Strategic Leaders as companies that provide a ric
Andersen Consulting Adds Collaborating Firm Vivaldi29.10.2025 15:30:00 EET | Press release
Andersen Consulting announces a Collaboration Agreement with Vivaldi, a global business and brand strategy consultancy, strengthening the organization’s strategy and business transformation offerings. Founded in 1999, Vivaldi is known for its approach to converge brand, business, and technology to keep clients in their leadership position. Operating in the U.S., Europe, and Latin America, Vivaldi works with leading global companies to build strong market positions, accelerate innovation, and design customer-centric business models. In today’s fast-evolving world shaped by AI, platform dynamics, and continuous reinvention, Vivaldi helps clients reimagine how business value is created and captured. The firm’s multidisciplinary teams blend deep consumer insight and market foresight with strategic, creative, and financial rigor to deliver tailored solutions for growth, transformation, and long-term competitiveness across industries. “Today’s business landscape demands that organizations le
Ferring Pharmaceuticals to Explore Strategic Options for Rebyota ®29.10.2025 15:00:00 EET | Press release
As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota® (faecal microbiota, live – jslm). To date, more than five thousand patients suffering from recurrent Clostridioides difficile infection (rCDI) have found new hope when treated with Rebyota®. Without commercial critical mass in this therapy area at Ferring, we believe that this first-in-class, innovative product could benefit many more patients with a new approach to its continued commercialisation. As a result, Ferring will reduce commercial efforts in the United States while ensuring uninterrupted access for patients. Approved by the U.S. Food and Drug Administration (FDA) in 2022, Rebyota® was the first FDA-approved faecal microbiota transplant, indicated for the prevention of rCDI in adults following antibiotic treatment for recurrent CDI. This milestone marked a significant advancement in understanding the role of the human microbiome in health and disease. Ferring
GigaDevice GD32F5xx and GD32G5xx Software Test Libraries (STL) Receive TÜV Rheinland IEC 61508 Functional Safety Certification29.10.2025 15:00:00 EET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, announced that its GD32F5xx and GD32G5xx Software Test Libraries have received IEC 61508 SC3 (SIL 2/SIL 3) functional safety certification from TÜV Rheinland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029124621/en/ Certificate This milestone expands GigaDevice’s functional safety portfolio, which already includes the GD32H7 and GD32F30x STLs, and now covers a broad range of MCUs with Arm® Cortex®-M7, Cortex®-M4, and Cortex®-M33 cores. Building on this foundation, GigaDevice will continue to deliver high-performance and safety-focused hardware and software solutions for key applications such as industrial control, energy and power, and humanoid robotics. With the growing emphasis on safety across industries like industrial automation, functional safety has become a critical considerat
375ai Launches Data Layer for the Physical World on Solana29.10.2025 15:00:00 EET | Press release
375ai, an edge data intelligence company transforming the physical world into structured, machine-readable insights, today announced the launch of its mainnet on Solana. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028976994/en/ 375ai Launches Data Layer for the Physical World The physical world is generating more data than ever before, but most of it is invisible. Traffic systems, advertising platforms, and governments still rely on outdated infrastructure and fragmented data sources to understand how people and goods move through cities. Centralized data pipelines are expensive, slow, and often limited to incomplete or delayed insights. Meanwhile, AI systems are hungry for real world context not just synthetic inputs. Without structured, real time data, they can’t power smarter mobility, logistics, and safety solutions. 375ai enables real world data capture, unlocking a new category of physical AI infrastructure. At l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom